In this article by Pharma's Almanac Andy Lewis discusses how the AI is providing the real value in drug product development and explains why it is embedded into scientific workflows.
Andy highlights the AI-driven formulation design, modeling and decision support that allows accelerated high-risk early decisions such as formulation selection, thereby reducing the burden of experimentation, speeding iteration, and using actual human data.
He notes that Intrepid Labs AI integration into Quotient Sciences' Translational Pharmaceutics® platform is a clear example of measurable speed‑to‑clinic and API savings.
Read the full article on Pharma's Almanac website.